Background
Obesity is one of the defining health challenges of our time, affecting more than 1 billion people worldwide and contributing to millions of preventable deaths each year.
There are several options to manage obesity in adults. In this context, WHO has developed a draft guideline providing evidence-informed recommendations on the use of glucagon-like peptide-1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists for the treatment of obesity in adults. The recommendations of the draft guideline were formulated based on analyses of published scientific studies, values and preferences and consideration on the access to this intervention.
Scope and purpose
The guideline is intended to support countries at all income levels in building equitable, evidence-based, and sustainable obesity chronic care programs. GLP-1 therapy is presented as one of several interventions within a multimodal model of care.
With the peer review process completed, WHO now invites Member States, health professionals, researchers, civil society organizations, people living with obesity, and other stakeholders to provide comments on the draft guideline. Feedback is particularly sought on:
- The clarity and relevance of the recommendations;
- Considerations for implementation in diverse contexts;
- Additional evidence or country experiences that may strengthen the guidance.
Guidance on providing comments
Comments on the draft guideline will be accepted via the online form that can be accessed here from 12 September 2025 (12:30 CEST) to 27 September 2025 (23:59 CEST). Comments will be accepted only through the online form and must be accompanied by a completed and signed Declaration of Interest (DOI).
Contact
Please direct questions regarding the consultation and its outcome to NFS@who.int with the subject “Feedback GLP-1 guidelines".